Opendata, web and dolomites

IgEPath

IgEPath - Contributions of IgE-antibodies and IgE effector cells to host defense against pathogenic bacteria

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IgEPath project word cloud

Explore the words cloud of the IgEPath project. It provides you a very rough idea of what is the project "IgEPath" about.

specificity    career    acquisition    prof    allergies    vivo    exacerbation    toxins    secondary    reintegration    defense    mast    mc    knapp    ige    immunity    atopic    community    translation    strains    mechanisms    infectious    health    facilitates    critical    led    pathogens    sylvia    competence    causing    complementarily    contrast    pathogenic    expertise    supporting    investigates    effector    hypothesis    inspire    decipher    transgenic    innate    antibiotic    elusive    immune    induce    connecting    resistant    mouse    diseases    detrimental    vaccine    antibodies    infections    mcs    starkl    benefit    participate    dr    acquired    iges    physiologic    combination    functions    disease    vitro    fellowship    bactericidal    bacterial    models    infection    host    secondment    msc    reporting    bacteria    cells    experimental    invasive    bee    venom    toxin    idea    roles    company    basophils    industrial    pharmaceutical    transfer    combines    immunoglobulin    sensitivity    beneficial    allergic    mice    philipp   

Project "IgEPath" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAET WIEN 

Organization address
address: SPITALGASSE 23
city: WIEN
postcode: 1090
website: www.meduniwien.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website https://innere-med-1.meduniwien.ac.at/forschungslabor-infektionsbiologie-research-lab-infectionbiology/
 Total cost 166˙156 €
 EC max contribution 166˙156 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2015
 Duration (year-month-day) from 2015-08-03   to  2017-08-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) coordinator 166˙156.00

Map

 Project objective

In combination, Immunoglobulin E antibodies (IgEs) and IgE effector cells, most importantly mast cells (MCs) and basophils, are best known for their disease-causing roles in allergic conditions. MCs can also participate in innate host defense against pathogens and toxins. In contrast, physiologic functions of IgEs that benefit the host are still elusive. Dr. Philipp Starkl led a recent study reporting the critical role of IgEs and IgE effector cells in a beneficial type 2 immune response against bee venom in mice, supporting the idea that allergies represent defense mechanisms against toxins. Toxins that induce IgE development are also produced by various pathogenic bacteria. IgE production during bacterial infection has been considered detrimental since it is associated with the exacerbation of atopic diseases. This study investigates the hypothesis that toxin-specific IgEs can be important for acquired immunity against pathogenic bacteria by increasing the sensitivity, extent and specificity of the bactericidal MC response. The main objective of this study is to decipher the roles of IgEs and IgE effector cells in host defense against invasive secondary infections with antibiotic resistant pathogenic bacteria, which are a major health problem in Europe. The experimental approach facilitates knowledge transfer between the US and EU and complementarily combines the applicant’s expertise in type 2 immunity, IgEs and MCs (acquired in the US) and Prof. Sylvia Knapp’s competence in bacterial infections and involves in vivo mouse models of infection in transgenic mouse strains and MC in vitro models. The secondment in a pharmaceutical company will inspire collaboration and translation of results into vaccine development. This MSC fellowship will support the applicant’s career development by fostering acquisition of novel expertise in infectious diseases, collaboration with and reintegration into the European research community and connecting with the industrial sector.

 Publications

year authors and title journal last update
List of publications.
2016 Kaori Mukai, Mindy Tsai, Philipp Starkl, Thomas Marichal, Stephen J. Galli
IgE and mast cells in host defense against parasites and venoms
published pages: 581-603, ISSN: 1863-2297, DOI: 10.1007/s00281-016-0565-1
Seminars in Immunopathology 38/5 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IGEPATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IGEPATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

RESTRICTIONAPP (2019)

A multilinear approach to the restriction problem with applications to geometric measure theory, the Schrödinger equation and inverse problems

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More